Effect of poly ethylene glycol on the mechanical and thermal properties of bioactive poly(epsilon-caprolactone) melt extrudates for pharmaceutical applications
posted on 2017-12-07, 12:45authored byP. Douglas, Ahmad B. Albadarin, M. Sajjia, Chirangano Mangwandi, Manuel Kuhs, Maurice N. Collins, Gavin M. Walker
This paper investigates the effects of polyethylene glycol (PEG), on the mechanical and thermal properties of nalidixic acid/poly ε-caprolactone (NA)/PCL blends prepared by hot melt extrusion. The blends were characterized by tensile and flexural analysis, dynamic mechanical analysis, differential scanning calorimetry, thermogravimetric analysis and X-ray diffraction. Results show that loading PEG in the PCL had a detrimental effect on the tensile strength and toughness of the blends, reducing them by 20–40%. The partial miscibility of the PCL-PEG system, causes an increase in Tg. While increases in the crystallinity is attributed to the plasticisation effect of PEG and the nucleation effect of NA. The average crystal size increased by 8% upon PEG addition. Experimental data indicated that the addition of NA caused loss of the tensile strength and toughness of PCL. Thermal analysis of the PCL showed that on addition of the thermally unstable NA, thermal degradation occurred early and was autocatalytic. However, the NA did benefit from the heat shielding provided by the PCL matrix resulting in more thermally stable NA particles
History
Publication
International Journal of Pharmaceutics;500 (1-2), pp. 179-186
Publisher
Elsevier
Note
peer-reviewed
Rights
This is the author’s version of a work that was accepted for publication in International Journal of Pharmaceutics. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in International Journal of Pharmaceutics, 2016, 500 (1-2), pp, 179-186, https://doi.org/10.1016/j.ijpharm.2016.01.036